Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators

Abstract

The development of multidrug resistance (MDR) is one of the major challenges to the success of chemotherapy treatment of cancer. This phenomenon is often associated with the overexpression of the ATP-binding cassette (ABC) transporters P-gp (P-glycoprotein, ABCB1), multidrug resistance-associated protein 1, ABCC1 and breast cancer resistance protein, ABCG2 (BCRP). These transporters are constitutively expressed in many tissues playing relevant protective roles by the regulation of the permeability of biological membranes, but they are also overexpressed in malignant tissues. P-gp is the first efflux transporter discovered to be involved in cancer drug resistance, and over the years, inhibitors of this pump have been disclosed to administer them in combination with chemotherapeutic agents. Three generations of inhibitors of P-gp have been examined in preclinical and clinical studies; however, these trials have largely failed to demonstrate that coadministration of pump inhibitors elicits an improvement in therapeutic efficacy of antitumor agents, although some of the latest compounds show better results. Therefore, new and innovative strategies, such as the fallback to natural products and the discover of dual activity ligands emerged as new perspectives. BCRP is the most recently ABC protein identified to be involved in multidrug resistance. It is overexpressed in several haematological and solid tumours together with P-gp, threatening the therapeutic effectiveness of different chemotherapeutic drugs. The chemistry of recently described BCRP inhibitors and dual P-gp/BCRP inhibitors, as well as their preliminary pharmacological evaluation are discussed, and the most recent advances concerning these kinds of MDR modulators are reviewed.

Keywords

Cancer / multidrug resistance / multidrug resistance modulators / ATP-binding cassette transporter inhibitors / P-glycoprotein / multidrug resistance-associated proteins / breast cancer resistance protein

References

[1] Phi LTH,Yang YG,Jun N.Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment..Stem Cells Int2018;2018:5416923 PMCID:PMC5850899

[2] Longley DB.Molecular mechanisms of drug resistance..J Pathol2005;205:275-92

[3] Chien AJ.Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired..Semin Oncol2008;35:S1-S14Quiz S39

[4] Kane SE.Testa B.Multidrug resistance of cancer cells..Advances in Drug Research vol.28.1996;New YorkAcademic Press181-252

[5] Mitscher LA,Gentry EJ.Multiple drug resistance..Med Res Rev1999;19:477-96

[6] Kaye SB.The multidrug resistance phenotype..Br J Cancer1988;58:691-4 PMCID:PMC2246872

[7] Holohan C,Longley DB.Cancer drug resistance: an evolving paradigm..Nat Rev Cancer2013;13:714-726

[8] Kartal-Yandim M,Baran Y.Molecular mechanisms of drug resistance and its reversal in cancer..Crit Rev Biotechnol.2016;36:716-26

[9] Fojo T.Strategies for reversing drug resistance..Oncogene2003;22:7512-23

[10] Raz S,Gonen N,Berman B.Severe hypoxia induces complete antifolate resistance in carcinoma cells due to cell cycle arrest..Cell Death Dis.2014;5:e1067 PMCID:PMC3944254

[11] Zhou X,Wang X,Zhu H.Galectin-1 is overexpressed in CD133+ human lung adenocarcinoma cells and promotes their growth and invasiveness..Oncotarget.2015;6:3111-22 PMCID:PMC4413641

[12] Bosch I.P-glycoprotein multidrug resistance and cancer..Biochim Biophys Acta1996;1288:F37-54

[13] Hrycyna CA.Multidrug ABC transporters from bacteria to man: an emerging hypothesis for the universality of molecular mechanism and function..Drug Resist Updat1998;1:81-3

[14] Gottesman MM,Bates SE.Multidrug resistance in cancer: role of ATP-dependent transporters..Nat Rev Cancer2002;2:48-58

[15] Chen Z,Zhang L,Deng M.Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade..Cancer Lett2016;370:153-64

[16] El-Awady R,Hashim A,Dallah A.The role of eukaryotic and prokaryotic ABC transporter family in failure of chemotherapy..Front Pharmacol2017;7:535 PMCID:PMC5223437

[17] Trock BJ,Clarke R.Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance..J Natl Cancer Inst1997;89:917-31

[18] Dean M.ABC transporters, drug resistance, and cancer stem cells..J Mammary Gland Biol Neoplasia2009;14:3-9

[19] Borst P.Mammalian ABC transporters in health and disease..Annu Rev Biochem2002;71:537-92

[20] Schinkel AH.Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview..Adv Drug Deliv Rev2003;55:3-29

[21] Ho RH.Transporters and drug therapy: implications for drug disposition and disease..Clin Pharmacol Ther2005;78:260-77

[22] Tarling EJ,Edwards PA.Role of ABC transporters in lipid transport and human disease..Trends Endocrinol Metab2013;24:342-50 PMCID:PMC3659191

[23] Cant N,Ford RC.CFTR structure and cystic fibrosis..Int J Biochem Cell Biol2014;52:15-25

[24] Gottesman MM.Biochemistry of multidrug resistance mediated by the multidrug transporter..Annu Rev Biochem1993;62:385-427

[25] Rosenberg MF,Ford RC.Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis..J Biol Chem1997;272:10685-94

[26] Callaghan R,Bebawy M.Inhibition of the multidrug resistance P-glycoprotein: time for a change in strategy?.Drug Metab Dispos2014;42:623-631 PMCID:PMC3965902

[27] Müller M,Jansen PL.Role of multidrug resistance protein (MRP) in glutathione S-conjugate transport in mammalian cells..J Hepatol1996;24:100-8

[28] Baiceanu E,Gonzalez-Lobato L,Baubichon-Cortay H.2-Indolylmethylenebenzofuranones as first effective inhibitors of ABCC2..Eur J Med Chem2016;122:408-18

[29] Lage H.Effect of the breast-cancer resistance protein on atypical multidrug resistance..Lancet Oncol2000;1:169-75

[30] Kawabata S,Shiozawa K,Nakatomi K.Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells..Biochem Biophys Res Commun2001;280:1216-23

[31] Horsey AJ,Sarwat S.The multidrug transporter ABCG2: still more questions than answers..Biochem Soc Trans2016;44:824-30 PMCID:PMC4900755

[32] Rosenberg MF,Callaghan R,Ford RC.Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding..J Biol Chem2003;278:8294-9

[33] Wu Yj,Wei W.The effects of DMARDs on the expression and function of P-gp, MRPs, BCRP in the treatment of autoimmune diseases..Biomed Pharmacother.2018;105:870-8

[34] Jardetzky O.Simple allosteric model for membrane pumps..Nature1966;211:969-70

[35] Senior AE,Urbatsch IL.The catalytic cycle of P-glycoprotein..FEBS Lett1995;377:285-9

[36] Higgins CF.The ATP switch model for ABC transporters..Nat Struct Mol Biol2004;11:918-26

[37] Siarheyeva A,Sharom FJ.Characterization of an asymmetric occluded state of P-glycoprotein with two bound nucleotides: implications for catalysis..J Biol Chem2010;285:7575-86 PMCID:PMC2844205

[38] Dawson RJ.Structure of a bacterial multidrug ABC transporter..Nature2006;443:180-5

[39] Ward A,Yu J,Chang G.Flexibility in the ABC transporter MsbA: Alternating access with a twist..Proc Natl Acad Sci U S A2007;104:19005-10 PMCID:PMC2141898

[40] Sharom FJ.The P-glycoprotein multidrug transporter..Essays Biochem2011;50:161-78

[41] Li J,Aller SG.Refined structures of mouse P-glycoprotein..Protein Sci2014;23:34-46 PMCID:PMC3892297

[42] Cole SP.Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future..Annu Rev Pharmacol Toxicol2014;54:95-117

[43] Abele R.Peptide trafficking and translocation across membranes in cellular signaling and self-defense strategies..Curr Opin Cell Biol2009;21:508-15

[44] Loo TW.The packing of the transmembrane segments of human multidrug resistance P-glycoprotein is revealed by disulfide cross-linking analysis..J Biol Chem2000;275:5253-6

[45] Pinkett HW,Lum P,Rees DC.An inward-facing conformation of a putative metal-chelate-type ABC transporter..Science2007;315:373-7

[46] Bolhuis H,Molenaar D,Driessen AJ.Multidrug resistance in Lactococcus lactis: evidence for ATP-dependent drug extrusion from the inner leaflet of the cytoplasmic membrane..EMBO J1996;15:4239-45 PMCID:PMC452149

[47] Wilkens S.Structure and mechanism of ABC transporters..F1000Prime Rep2015;7:14 PMCID:PMC4338842

[48] Juliano RL.A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants..Biochim Biophys Acta1976;455:152-62

[49] Jones PM.A new structural model for P-glycoprotein..J Membr Biol1998;166:133-147

[50] Ho GT,Satsangi J.Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?.Gut2003;52:759-66 PMCID:PMC1773632

[51] Loo TW.Merck Frosst Award Lecture 1998. Molecular dissection of the human multidrug resistance P-glycoprotein..Biochem Cell Biol1999;77:11-23

[52] Jones PM.Symmetry and structure in P-glycoprotein and ABC transporters what goes around comes around..Eur J Biochem2000;267:5298-305

[53] Aller SG,Ward A,Chittaboina S.Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding..Science2009;323:1718-22 PMCID:PMC2720052

[54] Choi YH.ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development..Curr Pharm Des2014;20:793-807 PMCID:PMC6341993

[55] Choudhuri S.Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters..Int J Toxicol2006;25:231-59

[56] Sharom FJ.ABC multidrug transporters: structure, function and role in chemoresistance..Pharmacogenomics2008;9:105-27

[57] Cole SP,Gerlach JH,Grant CE.Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line..Science1992;258:1650-4

[58] Cole SP.Multidrug resistance-associated protein: sequence correction..Science1993;260:879

[59] McGrath T.Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug..Cancer Res1988;48:3959-63

[60] Cole SPC,Fraser K,Grant CE.Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells..Cancer Res1994;54:5902-10

[61] Ozben T.Mechanisms and strategies to overcome multiple drug resistance in cancer..FEBS Lett2006;580:2903-9

[62] Rappa G,Flavell RA.Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins..Cancer Res1997;57:5232-7

[63] Renes J,Nienhuis EF,Müller M.ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1..Br J Pharmacol1999;126:681-8 PMCID:PMC1565864

[64] Ween MP,Oehler MK.The role of ABC transporters in ovarian cancer progression and chemoresistance..Crit Rev Oncol Hematol2015;96:220-56

[65] Krizkova V,Susova S,Bruha J.Protein expression of ATP-Binding cassette transporters ABCC10 and ABCC11 associates with survival of colorectal cancer patients..Cancer Chemother Pharmacol2016;78:595-603

[66] Doyle LA,Abruzzo LV,Gao Y.A multidrug resistance transporter from human MCF-7 breast cancer cells..Proc Natl Acad Sci USA1998;95:15665-70 PMCID:PMC28101

[67] Miyake K,Litman T,Robey R.Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes..Cancer Res1999;59:8-13

[68] Kage K,Sugiyama T,Ishikawa E.Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization..Int J Cancer2002;97:626-30

[69] Polgar O,Bates SE.ABCG2: structure, function and role in drug response..Expert Opin Drug Metab Toxicol2008;4:1-15

[70] Wang H,Cai X,Zhou L.Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence..Biochemistry2008;47:13778-87 PMCID:PMC2649121

[71] Wong K,Holliday ND.Plasma membrane dynamics and tetrameric organisation of ABCG2 transporters in mammalian cells revealed by single particle imaging techniques..Biochim Biophys Acta2016;1863:19-29

[72] Nakanishi T.Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression..Chin J Cancer2012;31:73-99 PMCID:PMC3777471

[73] Fletcher JI,Henderson MJ.ABC transporters in cancer: more than just drug efflux pumps..Nat Rev Cancer2010;10:147-56

[74] Haber M,Bordow SB,Cohn SL.Association of high-level MRPl expression with poor clinical outcome in a large prospective study of primary neuroblastoma..J Clin Oncol2006;24:1546-53

[75] Schaich M,Thiede C,Illmer T.MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia..Br J Haematol2005;128:324-32

[76] Suvannasankha A,O’Loughlin KL,Ford LA.Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival..Br J Haematol2004;127:392-8

[77] Yoh K,Yokose T,Tsuta K.Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer..Clin Cancer Res2004;10:1691-7

[78] Damiani D,Calistri E,Chiarvesio A.The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype..Haematologica2006;91:825-8

[79] Li W,Assaraf YG,Xu X.Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies..Drug Resist Updat2016;27:14-29

[80] Kathawala RJ,Ashby CR Jr.The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade..Drug Resist Updat2015;18:1-17

[81] Robert J.Multidrug resistance reversal agents..J Med Chem2003;46:4805-17

[82] Tsuruo T,Tsukagoshi S.Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil..Cancer Res1981;41:1967-72

[83] Szakács G,Ludwig JA,Gottesman MM.Targeting multidrug resistance in cancer..Nat Rev Drug Discov2006;5:219-34

[84] Palmeira A,Vasconcelos MH.Three decades of P-gp inhibitors: skimming through several generations and scaffolds..Curr Med Chem2012;19:1946-2025

[85] Waghray D.Inhibit or evade multidrug resistance P-glycoprotein in cancer treatment..J Med Chem2018;61:5108-21 PMCID:PMC6281405

[86] Wilson WH,Bryant G,Klecker RW.Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy..J Clin Oncol1995;13:1985-94

[87] Minderman H,Pendyala L.VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein..Clin Cancer Res2004;10:1826-34

[88] Tidefelt U,Gruber A,Sundman-Engberg B.P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia..J Clin Oncol2000;18:1837-44

[89] Lhommé C,Walker JL,Nicoletto MO.Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer..J Clin Oncol2008;26:2674-82

[90] Kolitz JE,Marcucci G,Powell BL.P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808..Blood2010;116:1413-21 PMCID:PMC2938834

[91] Luurtsema G,Klok RP,Leysen JE.Evaluation of [11C.laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats..Nucl Med Biol2009;36:643-9

[92] Chi KN,Dixon R,Wacher VJ.A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer..Invest New Drugs2005;23:311-5

[93] Kemper EM,Boogerd W,van Tellingen O.The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice..Cancer Chemother Pharmacol2004;53:173-8

[94] Dörner B,Bankstahl JP,Stanek J.Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier..J Med Chem2009;52:6073-82 PMCID:PMC3690441

[95] Fox E.Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor..Expert Rev Anticancer Ther2007;7:447-59

[96] Guns ES,Dixon R,Mayer L.Drug interaction studies between paclitaxel (Taxol) and OC144-093--a new modulator of MDR in cancer chemotherapy..Eur J Drug Metab Pharmacokinet2002;27:119-26

[97] Stewart A,Mellows G,Norris D.Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration..Clin Cancer Res2000;6:4186-91

[98] Darby RA,McMahon RM.P-glycoprotein inhibition: the past, the present and the future..Curr Drug Metab2011;12:722-31

[99] Coley HM.Overcoming multidrug resistance in cancer: clinical studies of P-glycoprotein inhibitors..Methods Mol Biol2010;596:341-58

[100] Cripe LD,Paietta EM,Ketterling RP.Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999..Blood2010;116:4077-85 PMCID:PMC2993615

[101] Kelly RJ,Chen CC,Figg WD.A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer..Clin Cancer Res2011;17:569-80 PMCID:PMC3071989

[102] Karthikeyan S.Development of fourth generation ABC inhibitors from natural products: a novel approach to overcome cancer multidrug resistance..Anticancer Agents Med Chem2015;15:605-15

[103] Ceballos MP,Cere LI,Catania VA.ABC transporters: Regulation and association with multidrug resistance in hepatocellular carcinoma and colorectal carcinoma..Curr Med Chem2018;25:1-26

[104] Ginwala R,Chigbu DI,Khan ZK.Potential Role of Flavonoids in Treating Chronic Inflammatory Diseases with a Special Focus on the Anti-Inflammatory Activity of Apigenin..Antioxidants (Basel)2019;8:pii:E35 PMCID:PMC6407021

[105] Morris ME.Flavonoid-drug interactions: effects of flavonoids on ABC transporters..Life Sci2006;78:2116-30

[106] Peña-Solórzano D,König B,Ochoa-Puentes C.ABCG2/BCRP: Specific and Nonspecific Modulators..Med Res Rev2017;37:987-1050

[107] Kiemlian Kwee J.Yin and Yang of Polyphenols in Cancer Prevention: A Short Review..Anticancer Agents Med Chem2016;16:832-40

[108] Pick A,Mayer R,Pajeva IK.Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP)..Bioorg Med Chem2011;19:2090-102

[109] Zhang S,Sagawa K.Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice..Drug Metab Dispos2005;33:341-8

[110] Yuan J,Jiang T,Liu T.Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells..Eur J Med Chem2012;54:413-22

[111] Ahmed-Belkacem A,Macalou S,Boumendjel A.Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2)..Anticancer Drugs2006;17:239-43

[112] Imai Y,Asada S.Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance..Cancer Res2004;64:4346-52

[113] An G.Effects of single and multiple flavonoids on BCRP-mediated accumulation, cytotoxicity and transport of mitoxantrone in vitro..Pharm Res2010;27:1296-308

[114] Zhang S,Morris ME.Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport..Mol Pharmacol2004;65:1208-16

[115] Hadjeri M,Ronot X,Boumendjel A.Modulation of P-glycoprotein-mediated multidrug resistance by flavonoid derivatives and analogues..J Med Chem2003;46:2125-31

[116] Juvale K,Wiese M.Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2..Eur J Med Chem2013;67:115-26

[117] Gallus J,Wiese M.Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity..Biochim Biophys Acta2014;1838:2929-38

[118] Valdameri G,Peres B,Guitton J.Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein..J Med Chem2012;55:966-70

[119] Winter E,Gozzi G,Lightbody M.Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2..J Med Chem2013;56:9849-60

[120] Pires ADRA,Guragossian N,Gozzi GJ.New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2..Eur J Med Chem2016;122:291-301

[121] van Loevezijn A,Schinkel AH.Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines..Bioorg Med Chem Lett2001;11:29-32

[122] Allen JD,Lakhai JM,van Tellingen O.Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C..Mol Cancer Ther2002;1:417-25

[123] Han Y,Go ML.Modulation of breast cancer resistance protein (BCRP/ABCG2) by non-basic chalcone analogues..Eur J Pharm Sci2008;35:30-41

[124] Boumendjel A,Champelovier P,Muhammad D.A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models..BMC Cancer2009;9:242 PMCID:PMC2717121

[125] Juvale K,Wiese M.Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein..Bioorg Med Chem2012;20:346-55

[126] Valdameri G,Terreux R,Day BJ.Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity..J Med Chem2012;55:3193-200 PMCID:PMC3983950

[127] Winter E,Chiaradia-Delatorre LD,Yunes RA.Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones..J Med Chem2014;57:2930-41

[128] Winter E,Chiaradia-Delatorre LD,Terreux R.Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position..Drug Des Devel Ther2014;8:609-19 PMCID:PMC4043709

[129] Kraege S,Juvale K,Willmes T.The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2)..Eur J Med Chem2016;117:212-29

[130] Juvale K,Wiese M.Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2)..Bioorg Med Chem2013;21:7858-73

[131] Stefan K.Untersuchung von chalkonen und flavonoiden als BCRP-inhibitoren (Master thesis), University of Bonn2011;

[132] Kraege S,Wiese M.Acryloylphenylcarboxamides: a new class of breast cancer resistance protein (ABCG2) modulators..ChemMedChem2016;11:2422-35

[133] Kraege S,Köhler SC.Optimization of acryloylphenylcarboxamides as inhibitors of ABCG2 and comparison with acryloylphenylcarboxylates..ChemMedChem2016;11:2547-58

[134] Silbermann K,Sahu NU,Stefan SM.Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2..Eur J Med Chem2019;164:193-213

[135] Chang JB,Li YF.Synthesis and biological activity of Wuweizisu C and analogs..Curr Top Med Chem2009;9:1660-75

[136] Jin J,Wei H.The anti-hepatitis drug DDB chemosensitizes multidrug resistant cancer cells in vitro and in vivo by inhibiting P-gp and enhancing apoptosis..Invest New Drugs2007;25:95-105

[137] Gu X,Tang X,Ma Y.Synthesis and biological evaluation of bifendate-chalcone hybrids as a new class of potential P-glycoprotein inhibitors..Bioorg Med Chem2012;20:2540-8

[138] Gu X,Peng H,Zhang Y.Bifendate-chalcone hybrids: a new class of potential dual inhibitors of P-glycoprotein and breast cancer resistance protein..Biochem Biophys Res Commun2014;455:318-22

[139] Gu X,Tang X,Zhao Q.Synthesis and biological evaluation of novel bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potent P-glycoprotein inhibitors..Eur J Med Chem2012;51:137-44

[140] Gu X,Zhao Q,Peng S.Discovery of alkoxyl biphenyl derivatives bearing dibenzo[c,e.azepine scaffold as potential dual inhibitors of P-glycoprotein and breast cancer resistance protein..Bioorg Med Chem Lett2014;24:3419-21

[141] Anuchapreeda S,Smith MM,Limtrakul PN.Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells..Biochem Pharmacol2002;64:573-82

[142] Chearwae W,Nandigama K,Limtrakul P.Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder..Biochem Pharmacol2004;68:2043-52

[143] Chearwae W,Limtrakul P.Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin..Mol Cancer Ther2006;5:1995-2006

[144] Murakami M,Fukuda M,Kudoh K.Synthetic Analogs of Curcumin Modulate the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCG2..Drug Metab Dispos2017;45:1166-77 PMCID:PMC5637816

[145] Pick A.Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway..ChemMedChem2012;7:650-62

[146] Krapf MK.Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2)..J Med Chem2016;59:5449-61

[147] Krapf MK,Wiese M.Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2)..Eur J Med Chem2017;139:587-611

[148] Krapf MK,Wiese M.4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2)..J Med Chem2017;60:4474-95

[149] Roe M,Ashworth P,Chima L.Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives..Bioorg Med Chem Lett1999;9:595-600

[150] Martin C,Mistry P,Charlton P.The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein..Br J Pharmacol1999;128:403-11 PMCID:PMC1571648

[151] Pusztai L,Ibrahim N,Theriault R.Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma..Cancer2005;104:682-91

[152] Pick A,Wiese M.Specific inhibitors of the breast cancer resistance protein (BCRP)..ChemMedChem2010;5:1498-1505

[153] Pajeva IK.Structure-activity relationships of tariquidar analogs as multidrug resistance modulators..AAPS J2009;11:435-44 PMCID:PMC2758111

[154] Marighetti F,Hanl M.Synthesis and quantitative structure-activity relationships of selective BCRP inhibitors..ChemMedChem2013;8:125-35

[155] Marighetti F,Karbaum M.Scaffold identification of a new class of potent and selective BCRP inhibitors..ChemMedChem2015;10:742-51

[156] Kwak JO,Lee GS,Ahn YG.Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel..Eur J Pharmacol2010;627:92-8

[157] Köhler SC.HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2)..J Med Chem2015;58:3910-21

[158] Köhler SC,Wiese M.Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter..Eur J Med Chem2016;124:881-95

[159] Köhler SC,Scholz MS.Structure activity relationships, multidrug resistance reversal and selectivity of heteroarylphenyl ABCG2 inhibitors..Eur J Med Chem2018;146:483-500

[160] Gujarati NA,Gupta P,Korlipara VL.Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors..Bioorg Med Chem Lett2017;27:4698-704

[161] Li XQ,Lei Y,Zhang FL.Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives..Eur J Med Chem2015;101:560-72

[162] Gao Y,Cui J,Bi X.Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as P-glycoprotein-mediated multidrug resistance inhibitors..Bioorg Med Chem2018;26:2420-7

[163] Peña-Solórzano D,Bernhardt G,König B.Tariquidar-Related Chalcones and Ketones as ABCG2 Modulators..ACS Med Chem Lett2018;9:854-9 PMCID:PMC6088357

[164] Teodori E,Bartolucci G,Manetti D.Structure-Activity Relationship Studies on 6,7-Dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline Derivatives as Multidrug Resistance Reversers..ChemMedChem2017;12:1369-79

[165] Li Y,Chmielecki J,Liao M.Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles..Bioorg Med Chem Lett2016;26:551-5

[166] Liao M,Zhu Q,Guan E.Preclinical absorption, distribution, metabolism, excretion and pharmacokinetics of a novel selective inhibitor of breast cancer resistance protein (BCRP)..Xenobiotica2018;48:467-77

[167] Ma Y.The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells..Phytother Res2010;24:146-9

[168] Spindler A,Wiese M.Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2)..J Med Chem2016;59:6121-35

[169] Ranjbar S,Edraki N,Saso L.Tetrahydroquinolinone derivatives as potent P-glycoprotein inhibitors: design, synthesis, biological evaluation and molecular docking analysis..Medchemcomm2017;8:1919-33 PMCID:PMC6072533

[170] Ranjbar S,Moreno A,Miri R.5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells..Toxicol Appl Pharmacol2019;362:136-149

[171] Stefan K,Wiese M.9-Deazapurines as Broad-Spectrum Inhibitors of the ABC Transport Proteins P-Glycoprotein, Multidrug Resistance-Associated Protein 1, and Breast Cancer Resistance Protein..J Med Chem2017;60:8758-80

[172] Schmitt SM,Wiese M.Pyrrolopyrimidine Derivatives as Novel Inhibitors of Multidrug Resistance-Associated Protein 1 (MRP1, ABCC1)..J Med Chem2016;59:3018-33

[173] Wang S,Harrison J,Chuckowree I.Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance..J Med Chem2004;47:1339-50

[174] Dantzic D,Merien F3,Lu J.The Effects of Synthetically Modified Natural Compounds on ABC Transporters..Pharmaceutics2018;10:pii:E127 PMCID:PMC6161255

[175] Schäfer A,Lohe M,Hiersemann M.Synthesis of Homoverrucosanoid-Derived Esters and Evaluation as MDR Modulators..J Org Chem2017;82:10504-22

[176] Rho JR,Sim CJ.Gagunins, highly oxygenated diterpenoids from the sponge Phorbas sp..Tetrahedron2002;58:9585-91

[177] Cramer J,Bates SE,Ecker GF.Multispecificity of drug transporters: probing inhibitor selectivity for the human drug efflux transporters ABCB1 and ABCG2..ChemMedChem2007;2:1783-8

[178] Schwarz T,Cseke A,Visvader L.Subtle Structural Differences Trigger Inhibitory Activity of Propafenone Analogues at the Two Polyspecific ABC Transporters: P-Glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP)..ChemMedChem2016;11:1380-94 PMCID:PMC4949556

[179] Kim BS,Jung HJ,Kwon HJ.HIF-1 suppressing small molecule, LW6, inhibits cancer cell growth by binding to calcineurin b homologous protein 1..Biochem Biophys Res Commun2015;458:14-20

[180] Song JG,Park JA,Lim SJ.Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein..Cancer Chemother Pharmacol2016;78:735-44

[181] Teodori E,Floriddia E,Manetti D.Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity..ChemMedChem2015;10:1339-43

[182] Orlandi F,Bellucci C,Guandalini L.New structure-activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR)..Bioorg Med Chem2013;21:456-65

[183] Dei S,Trezza A,Contino M.Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators..Eur J Med Chem2019;172:71-94

[184] Teodori E,Garnier-Suillerot A,Manetti D.Exploratory chemistry toward the identification of a new class of multidrug resistance reverters inspired by pervilleine and verapamil models..J Med Chem2005;48:7426-36

[185] Martelli C,Dei S,Orlandi F.Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors..J Med Chem2010;53:1755-62

[186] Dei S,Floriddia E,Bellucci C.Multidrug Resistance (MDR) reversers: high activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters..Eur J Med Chem2014;87:398-412

[187] Polli JW,Humphreys JE,Morgan JB.Rational use of in vitro P-glycoprotein assays in drug discovery..J Pharmacol Exp Ther.2001;299:620-8

[188] To KK,Wei Y,Lin G.Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia..Biochem Pharmacol.2015;97:27-37

[189] D'Cunha R,Murry DJ.TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux..Biopharm Drug Dispos.2016;37:397-408

[190] Fan YF,Zeng L,Cai CY.Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters..Cancer Lett.2018;421:186-98

[191] Zhang W,Cai CY,Teng QX.Olmutinib (BI1482694/HM61713), a novel epidermal growth factor receptor tyrosine kinase inhibitor, reverses ABCG2-mediated multidrug resistance in cancer cells..Front Pharmacol.2018;9:1097 PMCID:PMC6189370